Hematology
Volume 27, 2022 - Issue 1
Open access
9,464
Views
3
CrossRef citations to date
0
Altmetric
Research Article
Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis
Timothy Devosa Department of Hematology, University Hospitals Leuven (UZ Leuven) and Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), Catholic University Leuven (KU Leuven), Leuven, BelgiumCorrespondence[email protected]
https://orcid.org/0000-0002-6881-417XView further author information
Dominik Selleslagb Department of Hematology, Algemeen Ziekenhuis Sint-Jan, Bruges, BelgiumView further author information
, Nikki Granacherc Department of Hematology, Ziekenhuis Netwerk Antwerpen, Antwerp, BelgiumView further author information
, Violaine Havelanged Department of Hematology, Cliniques universitaires Saint-Luc, Brussels, Belgium
https://orcid.org/0000-0001-6061-6315View further author information
Fleur Samantha Benghiate Department of Hemato-Oncology, Erasme Hospital, Brussels, Belgium
https://orcid.org/0000-0002-2521-238XView further author information
Pages 23-31
|
Published online: 27 Dec 2021
Reprints and Permissions
This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, reproduction in any medium, provided the original work is properly cited.
You are not required to obtain permission to reuse this article in part or whole.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.